Thursday 16 October, 2025
Objectives: When assessing treatment effects in clinical studies by pharmacometrics modelling, type 1 error (T1) may be inflated in presence…
Read morePoster: Methodology - Other topics
Qualification of the Open Systems Pharmacology PBPK modeling Platform for simulation of transporter Drug-Drug-Interactions
Thursday 16 October, 2025
Introduction: The success of applications of Physiologically based pharmacokinetic (PBPK) modeling in drug development has led regulatory agencies to demand…
Read morenonmem2mrgsolve: An R package for Automated NONMEM to mrgsolve Translation
Thursday 16 October, 2025
Introduction: Pharmacometricians often utilize multiple software, with NONMEM® (ICON plc, Dublin, Ireland) widely regarded as the current gold standard for…
Read morePredicting Progression Free Survival from Measurable Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL)
Thursday 16 October, 2025
Introduction/Objectives: Measurable Residual Disease (MRD) is detectable and often quantifiable remnant cancer cells following treatment. The association between MRD and…
Read moreLeveraging Open Systems Biology Standards for Improved Reusability and Reproducibility of Pharmacological Models
Thursday 16 October, 2025
Introduction/Objectives: In systems biology, open standards for model exchange and storage have been designed to enable model transfer between computing…
Read moreR framework for reproducible and quality-controlled modeling and simulation with the Open Systems Pharmacology Software
Thursday 16 October, 2025
Objectives: Physiologically-based pharmacokinetic (PBPK) and quantitative systems pharmacology/toxicology (QSP/T) modeling are crucial tools in drug development and regulatory decision-making [1]….
Read moreStudying Targeted Protein Degradation Using a Quantitative Systems Pharmacology (QSP) Approach for Proteolysis Targeting Chimeras (PROTACs)
Thursday 16 October, 2025
Introduction: Targeted protein degradation is showing promising results for the treatment of various diseases, in particular cancer [1], mainly through…
Read moreTranslational pharmacology and dose rationale for imatinib and doramapimod as a host-directed therapy for the treatment of pulmonary tuberculosis
Thursday 16 October, 2025
Introduction: Tuberculosis (TB), the resulting disease of Mycobacterium tuberculosis (Mtb) infection, affects approximately 10 million people each year, despite drugs…
Read moreThe Applied Pharmacometrics Training Program – Year 3 Sustainability
Thursday 16 October, 2025
Objectives: The number of trained pharmacometricians on the African continent remains low, often driven by limited training opportunities and the…
Read moreMaS: population pharmacometric modeling in Python
Thursday 16 October, 2025
Introduction: MaS [1] is a software package for modeling and simulation in pharmacometrics and statistics. Its modeling language is built…
Read more